Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699503 | 1.00 | GLRA1 (0.52) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12233362 | 1.00 | GLRA1 (0.52) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL6043763 | 0.87 | GLRA1 (0.51) | GLRA1PDK1VNN1ALDH1A1MEN1 | |
| SCHEMBL15788121 | 0.84 | PDK1 (0.50) | GLRA1PDK1VNN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20671994 | 0.84 | MEN1 (0.44) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL22681134 | 0.83 | PDK1 (0.50) | GLRA1PDK1NPC1PKMPIK3CD | |
| SCHEMBL14773659 | 0.80 | CHRNB2 (0.42) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12206947 | 0.80 | CHRNB2 (0.42) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12206888 | 0.80 | CHRNB2 (0.42) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12331619 | 0.80 | CHRNB2 (0.42) | GLRA1PDK1CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-10266525-B2 | Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | BCL2L11, BCL2, BCL2L1 | GLRA1 3231/4885PDK1 1208/4885CHRNB2 4784/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GLRA1 3914/4885PDK1 439/4885CHRNB2 4378/4885 |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GLRA1 3917/4885PDK1 431/4885CHRNB2 4402/4885 |
| US-10266525-B2 | Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole | IPO4, CYP3A4, CYP4B1 | GLRA1 3662/4885PDK1 936/4885CHRNB2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.